SAN DIEGO (EGMN) - Even before it has earned a name, the novel targeted agent designated PCI-32765 is earning an impressive reputation, first for its mettle against chronic lymphocytic leukemia, and now for its potent action against relapsed or refractory mantle cell lymphoma in early clinical data, reported investigators at the annual meeting of the American Society of Hematology. Preliminary results of a phase II trial of PCI-32765, an inhibitor of...